NorthWest Biotherapeutics Inc (NWBO)

[Roman516]

NWBO's explanation to you, IMPO.
The OS data stands as is, "OS DATA GOLDEN"
Ditch the PFS statistical guess based on the OS results.
Fact is that DCVax-L works.
Fact is that DCVax-L added with other compounds improves overall performance and provides additional extended life results.
Dr. Linda Liau's early initial indications, 50% survival after 100 months.
NWBO has a path forward and that is a fact worthy for RA approvals, IMPO.
The latest version of the Flaskworks device has been tested and should be used
to increase the probability for higher vaccine production rates, 10x over standard
processes. Advanced automation capability is the objective and will enable NWBO's
manufacturing partners to meet the expected high demand once approved.
The good news is that the recent trial information supports DCVax-L data results of 50% to 55% with 100+ months of extended survival rate, IMPO. This is far better than the flux capacitor helmet by a factor of 4X to 5X, WOW, IMPO.